{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:29:54Z","timestamp":1793694594898,"version":"4.5.1"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"11","funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["R01CA148706"],"award-info":[{"award-number":["R01CA148706"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["R01CA240447"],"award-info":[{"award-number":["R01CA240447"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["R01NS128336"],"award-info":[{"award-number":["R01NS128336"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["P30GM133893"],"award-info":[{"award-number":["P30GM133893"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["KP1607011"],"award-info":[{"award-number":["KP1607011"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug resistance driven by efflux transporters and altered tubulin dynamics limits the clinical efficacy of taxanes and vincristine in high-risk neuroblastoma and castration-resistant prostate cancer. We developed QW-5-70, a colchicine binding site inhibitor (CBSI), engineered to retain low-nanomolar potency in both parental and drug-resistant cancer cells by showing minimal dependence on P-glycoprotein (P-gp)\u2013mediated efflux. QW-5-70 binds to the colchicine site on tubulin, inhibits tubulin polymerization, disrupts microtubule networks, and induces mitotic arrest. Across a panel of neuroblastoma and prostate cancer lines, QW-5-70 maintained low-nanomolar activity and remained effective in vincristine-resistant BE2C\/VCR and paclitaxel-resistant PC-3\/TxR cells. Unlike vincristine and paclitaxel, the activity and intracellular accumulation of QW-5-70 were unaffected by pharmacologic or genetic inhibition of P-gp, indicating effective circumvention of efflux-mediated resistance. In vitro, QW-5-70 significantly reduced colony formation and impaired migration in both parental and resistant cancer cells and induced G2\u2013M cell-cycle arrest and mitochondrial apoptosis. In vivo, QW-5-70 significantly suppressed tumor growth in drug-resistant PC-3\/TxR and BE2C\/VCR xenografts, with modest weight loss and no evident histopathology in the major organs. Combination studies revealed combination index\u2013defined synergistic interactions at selected dose pairs with the ornithine decarboxylase inhibitor \u03b1-difluoromethylornithine and enhanced apoptotic and clonogenic suppression when combined with the Aurora A kinase inhibitor MLN8237. Collectively, QW-5-70 is a potent CBSI that circumvents P-gp\u2013associated resistance, triggers mitotic arrest and apoptosis, and achieves significant antitumor activity in multidrug-resistant tumor models with acceptable tolerability, supporting its further preclinical development alone and in combination with other drugs.<\/jats:p>","DOI":"10.1158\/1535-7163.mct-25-1013","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:02:21Z","timestamp":1776870141000},"page":"1899-1912","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["QW-5-70 Targets the Colchicine Site and Demonstrates Antitumor Activity in P-gp\u2013Overexpressing Cancer Models"],"prefix":"10.1158","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-5152","authenticated-orcid":false,"given":"Yang","family":"Xie","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-8223","authenticated-orcid":false,"given":"Ruida","family":"Hou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-4519","authenticated-orcid":false,"given":"Najah","family":"Albadari","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3522-6531","authenticated-orcid":false,"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-511X","authenticated-orcid":false,"given":"Darcie J.","family":"Miller","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r3e0967","id-type":"ROR","asserted-by":"publisher"}],"name":"St. Jude Children\u2019s Research Hospital 2 Department of Structural Biology, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4375-8761","authenticated-orcid":false,"given":"Judith","family":"Quadrozzi Gruntz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r3e0967","id-type":"ROR","asserted-by":"publisher"}],"name":"St. Jude Children\u2019s Research Hospital 2 Department of Structural Biology, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9672-290X","authenticated-orcid":false,"given":"Michael L.","family":"Oldham","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r3e0967","id-type":"ROR","asserted-by":"publisher"}],"name":"St. Jude Children\u2019s Research Hospital 2 Department of Structural Biology, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-5449","authenticated-orcid":false,"given":"Mir Shahriar","family":"Kamal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-8928","authenticated-orcid":false,"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4511-3119","authenticated-orcid":false,"given":"Zhongzhi","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-0985","authenticated-orcid":false,"given":"Duane D.","family":"Miller","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-4474","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tennessee Health Science Center 1 Department of Pharmaceutical Sciences, College of Pharmacy, , Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026110303145301300_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2026110303145301300_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","article-title":"Advancing therapy for neuroblastoma","volume":"19","author":"Qiu","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110303145301300_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.20517\/cdr.2022.15","article-title":"Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo","volume":"5","author":"Yehya","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"2026110303145301300_bib4","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.3390\/cancers13225650","article-title":"Microtubule targeting agents in disease: classic drugs, novel roles","volume":"13","author":"Wordeman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026110303145301300_bib5","doi-asserted-by":"crossref","first-page":"804310","DOI":"10.3389\/fonc.2022.804310","article-title":"Vincristine, irinotecan, and temozolomide in patients with relapsed\/refractory neuroblastoma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"2026110303145301300_bib6","doi-asserted-by":"crossref","first-page":"7730","DOI":"10.3390\/ijms25147730","article-title":"Neuroblastoma-a review of combination immunotherapy","volume":"25","author":"Pieni\u0105\u017cek","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026110303145301300_bib7","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"2026110303145301300_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ccell.2015.01.008","article-title":"Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2","volume":"27","author":"Plymate","year":"2015","journal-title":"Cancer Cell"},{"key":"2026110303145301300_bib9","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0959-8049(97)00213-X","article-title":"Drug resistance in human neuroblastoma cell lines correlates with clinical therapy","volume":"33","author":"Keshelava","year":"1997","journal-title":"Eur J Cancer"},{"key":"2026110303145301300_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.biopha.2017.10.041","article-title":"New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer","volume":"96","author":"Zhang","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2026110303145301300_bib11","doi-asserted-by":"crossref","first-page":"29448","DOI":"10.1021\/acsomega.3c02979","article-title":"Effect of colchicine binding site inhibitors on the tubulin intersubunit interaction","volume":"8","author":"Sargsyan","year":"2023","journal-title":"ACS Omega"},{"key":"2026110303145301300_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1535-7163.MCT-19-0536","article-title":"An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance","volume":"19","author":"Deng","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026110303145301300_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2020.09.004","article-title":"Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer","volume":"495","author":"Mahmud","year":"2020","journal-title":"Cancer Lett"},{"key":"2026110303145301300_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12935-019-1072-y","article-title":"Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"2026110303145301300_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccr.2013.05.005","article-title":"Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-myc in childhood neuroblastoma","volume":"24","author":"Brockmann","year":"2013","journal-title":"Cancer Cell"},{"key":"2026110303145301300_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41416-024-02599-6","article-title":"Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway","volume":"130","author":"Yang","year":"2024","journal-title":"Br J Cancer"},{"key":"2026110303145301300_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jmb.2011.07.029","article-title":"The determinants that govern microtubule assembly from the atomic structure of GTP-tubulin","volume":"412","author":"Nawrotek","year":"2011","journal-title":"J Mol Biol"},{"key":"2026110303145301300_bib18","doi-asserted-by":"crossref","first-page":"12049","DOI":"10.1021\/acs.jmedchem.1c00715","article-title":"Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-Aryl-2-benzoyl-pyridines as potential anticancer agents","volume":"64","author":"Chen","year":"2021","journal-title":"J Med Chem"},{"key":"2026110303145301300_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2026110303145301300_bib20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"2026110303145301300_bib21","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.3390\/ijms21186811","article-title":"Gene expression signature of acquired chemoresistance in neuroblastoma cells","volume":"21","author":"Jema\u00e0","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026110303145301300_bib22","doi-asserted-by":"crossref","first-page":"118021","DOI":"10.1016\/j.ejmech.2025.118021","article-title":"Design and synthesis of novel 4-aryl-2-benzoyl-imidazoles as colchicine binding site inhibitors","volume":"298","author":"Albadari","year":"2025","journal-title":"Eur J Med Chem"},{"key":"2026110303145301300_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"2026110303145301300_bib24","doi-asserted-by":"crossref","first-page":"216046","DOI":"10.1016\/j.canlet.2022.216046","article-title":"SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis","volume":"555","author":"Deng","year":"2023","journal-title":"Cancer Lett"},{"key":"2026110303145301300_bib25","first-page":"5803","article-title":"Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells","volume":"61","author":"Kavallaris","year":"2001","journal-title":"Cancer Res"},{"key":"2026110303145301300_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/acsptsci.2c00108","article-title":"Design, synthesis, and biological evaluation of pyrimidine dihydroquinoxalinone derivatives as tubulin colchicine site-binding agents that displayed potent anticancer activity both in vitro and in vivo","volume":"6","author":"Pochampally","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026110303145301300_bib27","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1158\/0008-5472.CAN-11-4072","article-title":"Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-\u03b1-independent apoptosis","volume":"72","author":"Eschenburg","year":"2012","journal-title":"Cancer Res"},{"key":"2026110303145301300_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12575-010-9029-5","article-title":"Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site","volume":"12","author":"Fortin","year":"2010","journal-title":"Biol Proced Online"},{"key":"2026110303145301300_bib29","doi-asserted-by":"crossref","first-page":"R1287","DOI":"10.1016\/j.cub.2017.10.044","article-title":"Causes and consequences of microtubule acetylation","volume":"27","author":"Janke","year":"2017","journal-title":"Curr Biol"},{"key":"2026110303145301300_bib30","doi-asserted-by":"crossref","first-page":"108676","DOI":"10.1016\/j.bioorg.2025.108676","article-title":"Discovery of novel combretastatin A4 derivatives as a microtubule targeting agent capable of inducing HepG-2 cell apoptosis via the mitochondria and ER stress mediated pathway","volume":"163","author":"Huang","year":"2025","journal-title":"Bioorg Chem"},{"key":"2026110303145301300_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.leu.2402090","article-title":"Phosphorylation of Bcl2 and regulation of apoptosis","volume":"15","author":"Ruvolo","year":"2001","journal-title":"Leukemia"},{"key":"2026110303145301300_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/0008-5472.CAN-17-0577","article-title":"A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance","volume":"78","author":"Arnst","year":"2018","journal-title":"Cancer Res"},{"key":"2026110303145301300_bib33","doi-asserted-by":"crossref","first-page":"114392","DOI":"10.1016\/j.biopha.2023.114392","article-title":"Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies","volume":"160","author":"Hashemi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026110303145301300_bib34","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of taxane resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026110303145301300_bib35","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.3390\/cancers15174236","article-title":"Genetics of ABCB1 in cancer","volume":"15","author":"Skinner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026110303145301300_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review)","volume":"63","author":"Tian","year":"2023","journal-title":"Int J Oncol"},{"key":"2026110303145301300_bib37","doi-asserted-by":"crossref","first-page":"576559","DOI":"10.3389\/fonc.2020.576559","article-title":"P-glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers","volume":"10","author":"Seelig","year":"2020","journal-title":"Front Oncol"},{"key":"2026110303145301300_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12935-024-03415-0","article-title":"Key genes and molecular mechanisms related to paclitaxel resistance","volume":"24","author":"Alalawy","year":"2024","journal-title":"Cancer Cell Int"},{"key":"2026110303145301300_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2017.05.016","article-title":"BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549\/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe","volume":"402","author":"Bai","year":"2017","journal-title":"Cancer Lett"},{"key":"2026110303145301300_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.canlet.2016.09.007","article-title":"Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells","volume":"383","author":"Wen","year":"2016","journal-title":"Cancer Lett"},{"key":"2026110303145301300_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-016-0332-0","article-title":"Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell","volume":"35","author":"Hasanpourghadi","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"2026110303145301300_bib42","doi-asserted-by":"crossref","first-page":"110456","DOI":"10.1016\/j.jbc.2025.110456","article-title":"Dynamic regulation of Sec24C by phosphorylation and O-GlcNAcylation during cell cycle progression","volume":"301","author":"Georgiou","year":"2025","journal-title":"J Biol Chem"},{"key":"2026110303145301300_bib43","doi-asserted-by":"crossref","first-page":"e24312","DOI":"10.1371\/journal.pone.0024312","article-title":"Role of cyclin B1\/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole","volume":"6","author":"Choi","year":"2011","journal-title":"PLoS One"},{"key":"2026110303145301300_bib44","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cub.2014.01.033","article-title":"Dependency of the spindle assembly checkpoint on Cdk1 renders the anaphase transition irreversible","volume":"24","author":"Rattani","year":"2014","journal-title":"Curr Biol"},{"key":"2026110303145301300_bib45","doi-asserted-by":"crossref","first-page":"e7207","DOI":"10.1002\/cam4.7207","article-title":"DFMO inhibition of neuroblastoma tumorigenesis","volume":"13","author":"Gandra","year":"2024","journal-title":"Cancer Med"},{"key":"2026110303145301300_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2024.04.005","article-title":"Eflornithine for treatment of high-risk neuroblastoma","volume":"45","author":"Jiang","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"2026110303145301300_bib47","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/jcm14041068","article-title":"Polyamine inhibition with DFMO: shifting the paradigm in neuroblastoma therapy","volume":"14","author":"Schramm","year":"2025","journal-title":"J Clin Med"},{"key":"2026110303145301300_bib48","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","article-title":"Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma","volume":"18","author":"Mahadevan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026110303145301300_bib49","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1172\/JCI132184","article-title":"Taxane resistance in prostate cancer is mediated by decreased drug-target engagement","volume":"130","author":"Gjyrezi","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/doi\/10.1158\/1535-7163.MCT-25-1013\/3774785\/mct-25-1013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/doi\/10.1158\/1535-7163.MCT-25-1013\/3778930\/mct-25-1013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/25\/11\/1899\/3844692\/mct-25-1013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/25\/11\/1899\/3844692\/mct-25-1013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:15:09Z","timestamp":1793693709000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/25\/11\/1899\/789670\/QW-5-70-Targets-the-Colchicine-Site-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-25-1013","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1535-7163.c.8814697","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1535-7163.34897504","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897513","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897501","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897507","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897516","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897495","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897474","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897483","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897477","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897489","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897510","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897498","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897480","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.34897492","asserted-by":"object"}]},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}